ClinicalTrials.gg
CompletedNCT02986373Updated May 28, 2019Results posted

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

A Phase 2 interventional study of risankizumab in Psoriatic Arthritis, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-28.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Enrollment
10th of 11
145 · median 246
Started
2016
with 4 others
Phase 2
5 of 34
1 open now
Registered
20th of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2016, is one of 5 in phase 2, and was the 20th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability of risankizumab in participants with psoriatic arthritis (PsA).

Read the detailed description

Participants who had completed all doses of study drug and the Week 24 visit of M16-002 (NCT02719171; the lead-in study) were eligible to enroll in M16-244 (this study). Participants were allowed to either finish the Week 24 visit of the lead-in study and take the first dose of study drug for this study on the same day, or delay the start of this study up to 8 weeks if needed.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • risankizumab
  • ABBV-066
  • BI655066
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have completed all doses of study drug and Week 24 visit of the lead-in study.
  • Women of who are sexually active, must agree to use at least one accepted method of throughout the study, including 20 weeks after last dose of study drug is given.
  • Women of childbearing potential must have a negative urine pregnancy test at Baseline (Week 0/V1).
  • Participants must voluntarily sign and date an , approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any study specific procedures.
  • Participant is judged to be in good health as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Female participant who is pregnant, breastfeeding or is considering becoming pregnant during study participation, including 20 weeks after the last dose of study drug is given.
  • Premature discontinuation of the study drug in the lead-in study for any reason.
  • Use of a biologic treatment other than risankizumab since first dose of study drug in the lead-in study.
  • Time elapsed is > 8 weeks since the Week 24 visit in the lead-in study.
  • Active systemic infections during the last 2 weeks (exception: common cold) prior to the first dose, as assessed by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.

    Biological: risankizumab

Interventions

  • Biologicalrisankizumab

    Risankizumab administered by subcutaneous injection.

    Also known as: ABBV-066, BI 655066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs) are defined as an AE that began or worsened in severity after initiation of study drug and 20 weeks (140 days) after last dose. Abbreviations: NMSC=non-melanoma skin cancer

    Time frame: From the first dose of study drug in this study until 20 weeks after the last dose of study drug (up to 56 weeks).

Secondary outcomes

  1. Modified Total Sharp Score (mTSS): Change From Baseline (in the Lead-in Study) to Week 24 in the Lead-in Study

    The mTSS is a measure of change in joint health. X-rays of hands, wrists, and feet (including distal interphalangeal joints) were obtained at Week 24 and Week 48. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening; no progression was defined as a change of ≤0.5. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 24 (Lead-in Study)

  2. mTSS: Change From Baseline (in the Lead-in Study) to Week 24

    The mTSS is a measure of change in joint health. X-rays of hands, wrists, and feet (including distal interphalangeal joints) were obtained at Week 24 and Week 48. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening; no progression was defined as a change of ≤0.5. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 24

  3. mTSS: Change From Baseline (in the Lead-in Study) to Week 48

    The mTSS is a measure of change in joint health. X-rays of hands, wrists, and feet (including distal interphalangeal joints) were obtained at Week 24 and Week 48. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening; no progression was defined as a change of ≤0.5. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 48

  4. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 0

    Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 0: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity visual analog scale (VAS), Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, Health Assessment Questionnaire Disability Index (HAQ-DI), and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

    Time frame: Week 0

  5. Percentage of Participants Achieving ACR20 Response at Week 4

    Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 4: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

    Time frame: Week 4

  6. Percentage of Participants Achieving ACR20 Response at Week 12

    Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 12: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

    Time frame: Week 12

  7. Percentage of Participants Achieving ACR20 Response at Week 24

    Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 24: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

    Time frame: Week 24

  8. Percentage of Participants Achieving ACR20 Response at Week 36

    Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 36: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

    Time frame: Week 36

  9. Percentage of Participants Achieving ACR20 Response at Week 48

    Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 48: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

    Time frame: Week 48

  10. Percentage of Participants Achieving ACR20 Response at Week 52

    Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 52: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

    Time frame: Week 52

  11. Health Assessment Questionnaire Disability Index (HAQ-DI): Change From Baseline (in the Lead-in Study) to Week 0

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 0

  12. HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 4

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 4

  13. HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 12

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 12

  14. HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 24

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 24

  15. HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 36

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 36

  16. HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 48

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 48

  17. HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 52

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 52

  18. Short Form Health Survey 36 (SF-36) Physical Component Summary (PCS) Score: Change From Baseline (in the Lead-in Study) to Week 0

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 0

  19. SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 4

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 4

  20. SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 12

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 12

  21. SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 24

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 24

  22. SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 36

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 36

  23. SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 48

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 48

  24. SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 52

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 52

  25. SF-36 Mental Component Summary (MCS) Score: Change From Baseline (in the Lead-in Study) to Week 0

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 0

  26. SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 4

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 4

  27. SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 12

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 12

  28. SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 24

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 24

  29. SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 36

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 36

  30. SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 48

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 48

  31. SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 52

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

    Time frame: Baseline (Lead-in Study), Week 52

07

Results

Posted May 28, 2019

Participant flow

Participant flow — Overall Study
MilestoneRisankizumab
Started145
Completed106
Not completed39
Withdrew: Adverse event4
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject10
Withdrew: Other24

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs) are defined as an AE that began or worsened in severity after initiation of study drug and 20 weeks (140 days) after last dose. Abbreviations: NMSC=non-melanoma skin cancer

Time frame:
From the first dose of study drug in this study until 20 weeks after the last dose of study drug (up to 56 weeks).
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsRisankizumab
Any AE87
Any AE at least possibly drug related22
Any SAE at least possibly drug related1
Any severe AE7
Any SAE5
Any AE leading to discontinuation of study drug5
Any major adverse cardiac events (by adjudication)2
Any Serious Infections Events2
Any tuberculosis events2
Any malignant tumor events1
Any malignancies excluding NMSC events1
SecondaryModified Total Sharp Score (mTSS): Change From Baseline (in the Lead-in Study) to Week 24 in the Lead-in Study

The mTSS is a measure of change in joint health. X-rays of hands, wrists, and feet (including distal interphalangeal joints) were obtained at Week 24 and Week 48. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening; no progression was defined as a change of ≤0.5. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 24 (Lead-in Study)
Reported as:
Mean · units on a scale
Modified Total Sharp Score (mTSS): Change From Baseline (in the Lead-in Study) to Week 24 in the Lead-in Study
units on a scaleRisankizumab
Modified Total Sharp Score (mTSS): Change From Baseline (in the Lead-in Study) to Week 24 in the Lead-in Study0.12 (-0.16 to 0.40)
SecondarymTSS: Change From Baseline (in the Lead-in Study) to Week 24

The mTSS is a measure of change in joint health. X-rays of hands, wrists, and feet (including distal interphalangeal joints) were obtained at Week 24 and Week 48. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening; no progression was defined as a change of ≤0.5. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 24
Reported as:
Mean · units on a scale
mTSS: Change From Baseline (in the Lead-in Study) to Week 24
units on a scaleRisankizumab
mTSS: Change From Baseline (in the Lead-in Study) to Week 240.38 (0.06 to 0.71)
SecondarymTSS: Change From Baseline (in the Lead-in Study) to Week 48

The mTSS is a measure of change in joint health. X-rays of hands, wrists, and feet (including distal interphalangeal joints) were obtained at Week 24 and Week 48. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening; no progression was defined as a change of ≤0.5. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 48
Reported as:
Mean · units on a scale
mTSS: Change From Baseline (in the Lead-in Study) to Week 48
units on a scaleRisankizumab
mTSS: Change From Baseline (in the Lead-in Study) to Week 480.34 (-0.07 to 0.75)
SecondaryPercentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 0

Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 0: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity visual analog scale (VAS), Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, Health Assessment Questionnaire Disability Index (HAQ-DI), and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

Time frame:
Week 0
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 0
percentage of participantsRisankizumab
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 043.4 (35.2 to 51.9)
SecondaryPercentage of Participants Achieving ACR20 Response at Week 4

Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 4: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response at Week 4
percentage of participantsRisankizumab
Percentage of Participants Achieving ACR20 Response at Week 455.6 (47.1 to 63.8)
SecondaryPercentage of Participants Achieving ACR20 Response at Week 12

Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 12: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response at Week 12
percentage of participantsRisankizumab
Percentage of Participants Achieving ACR20 Response at Week 1257.0 (48.5 to 65.3)
SecondaryPercentage of Participants Achieving ACR20 Response at Week 24

Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 24: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response at Week 24
percentage of participantsRisankizumab
Percentage of Participants Achieving ACR20 Response at Week 2462.7 (53.9 to 70.9)
SecondaryPercentage of Participants Achieving ACR20 Response at Week 36

Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 36: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response at Week 36
percentage of participantsRisankizumab
Percentage of Participants Achieving ACR20 Response at Week 3668.7 (59.4 to 77.0)
SecondaryPercentage of Participants Achieving ACR20 Response at Week 48

Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 48: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response at Week 48
percentage of participantsRisankizumab
Percentage of Participants Achieving ACR20 Response at Week 4869.7 (60.2 to 78.2)
SecondaryPercentage of Participants Achieving ACR20 Response at Week 52

Response defined by ACR20 criteria (improvement from baseline in the lead-in study) at Week 52: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 out of the following 5 parameters: Patient's Assessment of Pain Intensity VAS, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, HAQ-DI, and acute phase reactant value (C-reactive protein). Baseline is defined as the last non missing pre-treatment observation prior to first dose in the lead-in study.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response at Week 52
percentage of participantsRisankizumab
Percentage of Participants Achieving ACR20 Response at Week 5275.2 (65.7 to 83.3)
SecondaryHealth Assessment Questionnaire Disability Index (HAQ-DI): Change From Baseline (in the Lead-in Study) to Week 0

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 0
Reported as:
Mean · units on a scale
Health Assessment Questionnaire Disability Index (HAQ-DI): Change From Baseline (in the Lead-in Study) to Week 0
units on a scaleRisankizumab
Health Assessment Questionnaire Disability Index (HAQ-DI): Change From Baseline (in the Lead-in Study) to Week 0-0.176 (-0.249 to -0.102)
SecondaryHAQ-DI: Change From Baseline (in the Lead-in Study) to Week 4

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 4
Reported as:
Mean · units on a scale
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 4
units on a scaleRisankizumab
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 4-0.258 (-0.332 to -0.183)
SecondaryHAQ-DI: Change From Baseline (in the Lead-in Study) to Week 12

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 12
Reported as:
Mean · units on a scale
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 12
units on a scaleRisankizumab
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 12-0.261 (-0.336 to -0.186)
SecondaryHAQ-DI: Change From Baseline (in the Lead-in Study) to Week 24

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 24
Reported as:
Mean · units on a scale
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 24
units on a scaleRisankizumab
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 24-0.296 (-0.374 to -0.217)
SecondaryHAQ-DI: Change From Baseline (in the Lead-in Study) to Week 36

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 36
Reported as:
Mean · units on a scale
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 36
units on a scaleRisankizumab
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 36-0.294 (-0.384 to -0.204)
SecondaryHAQ-DI: Change From Baseline (in the Lead-in Study) to Week 48

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 48
Reported as:
Mean · units on a scale
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 48
units on a scaleRisankizumab
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 48-0.298 (-0.381 to -0.215)
SecondaryHAQ-DI: Change From Baseline (in the Lead-in Study) to Week 52

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 52
Reported as:
Mean · units on a scale
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 52
units on a scaleRisankizumab
HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 52-0.318 (-0.405 to -0.231)
SecondaryShort Form Health Survey 36 (SF-36) Physical Component Summary (PCS) Score: Change From Baseline (in the Lead-in Study) to Week 0

The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 0
Reported as:
Median · units on a scale
Short Form Health Survey 36 (SF-36) Physical Component Summary (PCS) Score: Change From Baseline (in the Lead-in Study) to Week 0
units on a scaleRisankizumab
Short Form Health Survey 36 (SF-36) Physical Component Summary (PCS) Score: Change From Baseline (in the Lead-in Study) to Week 02.11 (0.89 to 3.34)
SecondarySF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 4

The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 4
Reported as:
Median · units on a scale
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 4
units on a scaleRisankizumab
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 43.63 (2.41 to 4.85)
SecondarySF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 12

The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 12
Reported as:
Median · units on a scale
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 12
units on a scaleRisankizumab
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 123.63 (2.32 to 4.94)
SecondarySF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 24

The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 24
Reported as:
Median · units on a scale
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 24
units on a scaleRisankizumab
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 243.76 (2.50 to 5.02)
SecondarySF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 36

The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 36
Reported as:
Median · units on a scale
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 36
units on a scaleRisankizumab
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 364.27 (2.97 to 5.57)
SecondarySF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 48

The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 48
Reported as:
Median · units on a scale
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 48
units on a scaleRisankizumab
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 485.08 (3.66 to 6.50)
SecondarySF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 52

The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 52
Reported as:
Median · units on a scale
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 52
units on a scaleRisankizumab
SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 524.47 (3.11 to 5.84)
SecondarySF-36 Mental Component Summary (MCS) Score: Change From Baseline (in the Lead-in Study) to Week 0

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 0
Reported as:
Median · units on a scale
SF-36 Mental Component Summary (MCS) Score: Change From Baseline (in the Lead-in Study) to Week 0
units on a scaleRisankizumab
SF-36 Mental Component Summary (MCS) Score: Change From Baseline (in the Lead-in Study) to Week 00.86 (-0.64 to 2.35)
SecondarySF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 4

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 4
Reported as:
Median · units on a scale
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 4
units on a scaleRisankizumab
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 42.79 (1.27 to 4.31)
SecondarySF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 12

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 12
Reported as:
Median · units on a scale
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 12
units on a scaleRisankizumab
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 122.22 (0.49 to 3.96)
SecondarySF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 24

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 24
Reported as:
Median · units on a scale
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 24
units on a scaleRisankizumab
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 244.08 (2.39 to 5.77)
SecondarySF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 36

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 36
Reported as:
Median · units on a scale
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 36
units on a scaleRisankizumab
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 363.44 (1.60 to 5.28)
SecondarySF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 48

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 48
Reported as:
Median · units on a scale
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 48
units on a scaleRisankizumab
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 483.36 (1.40 to 5.31)
SecondarySF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 52

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement. Baseline is defined as baseline in the lead-in study.

Time frame:
Baseline (Lead-in Study), Week 52
Reported as:
Median · units on a scale
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 52
units on a scaleRisankizumab
SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 524.33 (2.56 to 6.10)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug in this study until 20 weeks after the last dose of study drug (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risankizumab0/145 (0%)5/145 (3.4%)16/145 (11%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventRisankizumab
ACUTE CORONARY SYNDROMECardiac disorders1/145
ANGINA PECTORISCardiac disorders1/145
ISCHAEMIC CARDIOMYOPATHYCardiac disorders1/145
PNEUMONIA HAEMOPHILUSInfections and infestations1/145
PNEUMONIA PSEUDOMONALInfections and infestations1/145
STAPHYLOCOCCAL INFECTIONInfections and infestations1/145
UROSEPSISInfections and infestations1/145
GLOMERULAR FILTRATION RATE ABNORMALInvestigations1/145
COLORECTAL CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/145
ISCHAEMIC STROKENervous system disorders1/145
Most frequent other events
Most frequent other events
EventRisankizumab
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations16/145

Baseline characteristics

Safety analysis set: consists of all participants who received at least 1 dose of study medication in Study M16-244.

Age, Continuous
Age, Continuous(years)Risankizumab
Mean50.4 ± 12.52
Sex: Female, Male
Sex: Female, Male(Participants)Risankizumab
Female61
Male84
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Risankizumab
Hispanic or Latino3
Not Hispanic or Latino138
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Risankizumab
American Indian or Alaska Native1
Asian21
Native Hawaiian or Other Pacific Islander0
Black or African American0
White119
More than one race0
Unknown or Not Reported4
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30. PubMed 36178584 ↗
  • Mease PJ, Kellner H, Morita A, Kivitz AJ, Aslanyan S, Padula SJ, Topp AS, Eldred A, Behrens F, Papp KA. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial. Rheumatol Ther. 2022 Oct;9(5):1361-1375. doi: 10.1007/s40744-022-00474-5. Epub 2022 Aug 5. PubMed 35931879 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jul 2018, 18 months.

Results were first posted in May 2019, 10 months after primary completion.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2016
First posted
Dec 8, 2016
StartActual
Dec 15, 2016
Primary completionActual
Jul 8, 2018
CompletionActual
Jul 30, 2018
Results first posted
May 28, 2019
Last update
May 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02986373
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 8, 2016
Start date
Dec 15, 2016
Primary completion
Jul 8, 2018
Completion
Jul 30, 2018
Results posted
May 28, 2019
Last update
May 28, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion